Drug Type Trispecific T-cell engager (TriTE) |
Synonyms CC312 |
Target |
Action inhibitors, modulators, stimulants |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD28 modulators(T-cell-specific surface glycoprotein CD28 modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Haemolytic Anaemias | Phase 1 | China | ![]() | 08 Nov 2024 |
Idiopathic Inflammatory Myopathies | Phase 1 | China | ![]() | 08 Nov 2024 |
Purpura, Thrombocytopenic, Idiopathic | Phase 1 | China | ![]() | 08 Nov 2024 |
Rheumatoid Arthritis | Phase 1 | China | ![]() | 08 Nov 2024 |
Scleroderma, Systemic | Phase 1 | China | ![]() | 08 Nov 2024 |
Systemic Lupus Erythematosus | Phase 1 | China | ![]() | 08 Nov 2024 |
Acute Lymphoblastic Leukemia | Phase 1 | China | ![]() | 07 Aug 2023 |
B-cell lymphoma refractory | Phase 1 | China | ![]() | 07 Aug 2023 |
B-Cell Malignant Neoplasm | Phase 1 | China | ![]() | 07 Aug 2023 |
Chronic Lymphocytic Leukemia | Phase 1 | China | ![]() | 07 Aug 2023 |